参考文献/References:
[1] Kramer CK，Borgono CA，Van Nostrand P，et al.Glucagon response to oral glucose challenge in type 1 diabetes：lack of impact of euglycemia[J].Diabetes Care，2014，37（4）：1076-1082.
[2] Downie E，Craig ME，Hing S，et al.Continued reduction in the prevalence of retinopathy in adolescents with type 1 diabetes：role of insulin therapy and glycemic control[J].Diabetes Care，2011，34（11）：2368-2373.
[3] Wood JR，Miller KM，Maahs DM，et al.Most youth with type 1 diabetes in the T1D Exchange Clinic Registry do not meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes clinical guidelines[J].Diabetes Care，2013，36（7）：2035-2037.
[4] Kuhadiya ND，Malik R，Bellini NJ，et al.Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus[J].Endocr Pract，2013，19（6）：963-967.
[5] Traina AN，Lull ME，Hui AC，et al.Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy[J].Can J Diabetes，2014，38（4）：269-272.
[6] Farngren J，Persson M，Schweizer A，et al.Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counter-regulation during hypoglycemia in type 1 diabetes[J].J Clin Endocrinol Metab，2012，97（10）：3799-3806.
[7] Ellis SL，Moser EG，Snell-Bergeon JK，et al.Effect of sitagliptin on glucose control in adult patients with type 1 diabetes：a pilot，double-blind，randomized，crossover trial[J].Diabet Med，2011，28（10）：1176-1181.
[8] Morrow L，Hompesch M，Guthrie H，et al.Co-administration of liraglutide with insulin detemir demonstrates additive pharma-codynamic effects with no pharmacokinetic interaction[J].Diabetes Obes Metab，2011，13（1）：75-80.
[9] Renukuntla VS，Ramchandani N，Trast J，et al.Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm[J].J Diabetes Sci Technol，2014，8（5）：1011-1017.
[10] Patel V，Joharapurkar A，Dhanesha N，et al.Combination of omeprazole with GLP-1 agonist therapy improves insulin sensi-tivity and antioxidant activity in liver in type 1 diabetic mice[J].Pharmacol Rep，2013，65（4）：927-936.
[11] Sarkar G，Alattar M，Brown RJ，et al.Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes[J]. Diabetes Care，2014，37（3）：666-670.
[12] Deiss D，Diederich S，Kordonouri O.Successful treatment with liraglutide in type 1 diabetes and MODY[J].Dtsch Med
Wochenschr，2011，136（21）：1116-1120.
[13] Harrison LB，Mora PF，Clark GO，et al.Type 1 diabetes treatment beyond insulin：role of GLP-1 analogs[J].J Investig Med，2013，
61（1）：40-44.
[14] Foley JE，Ligueros-Saylan M，He YL，et al.Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes[J].Horm Metab Res，2008，40（10）：727-730.
[15] Varanasi A，Bellini N，Rawal D，et al.Liraglutide as additional treatment for type 1 diabetes[J].Eur J Endocrinol，2011，165（1）：77-84.
[16] Kielgast U，Holst JJ，Madsbad S.Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual beta-cell function[J].Diabetes，2011，60（5）：1599-1607.
[17] Ghazi T，Rink L，Sherr JL，et al.Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges[J].Diabetes Care，2014，37（1）：210-216.
[18] Creutzfeldt WO，Kleine N，Willms B，et al.Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide Ⅰ（7-36） amide in type Ⅰ diabetic patients[J].Diabetes Care，1996，19（6）：580-586.
[19] Garg SK，Moser EG，Bode BW，et al.Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes：investigator-initiated，double-blind，randomized，placebo-controlled trial[J].Endocr Pract，2013，19（1）：19-28.
[20] Suarez-Pinzon WL，Rabinovitch A.Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor induces beta-cell neogenesis from adult human pancreatic duct cells implanted in immunodeficient mice[J].Cell Transplant，2011，20（9）：1343-1349.
[21] Cechin SR，Pérez-?魣lvarez I，Fenjves E，et al.Anti-inflammatory properties of exenatide in human pancreatic islets[J].Cell Transplant，2012，21（4）：633-648.
[22] Jelsing J，Vrang N，van Witteloostuijn SB，et al.The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves beta-cell mass in non-obese diabetic mice[J].J Endocrinol，2012，
214（3）：381-387.
[23] Cho JM，Jang HW，Cheon H，et al.A novel dipeptidyl peptidase Ⅳ inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing beta-cell replication and neogenesis[J].Diabetes Res Clin Pract，2011，91（1）：72-79.
[24] Drews G，Krippeit-Drews P，Düfer M.Oxidative stress and beta-cell dysfunction[J].Pflugers Arch，2010，460（4）：703-718.
[25] Zhao L，Guo H，Chen H，et al.Effect of liraglutide on endoplasmic reticulum stress in diabetes[J].Biochem Biophys Res Commun，2013，441（1）：133-138.
[26] Ceriello A，Novials A，Ortega E，et al.Glucagon-like peptide 1 reduces endothelial dysfunction， inflammation， and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes[J]. Diabetes Care，2013，36（8）：2346-2350.
[27] ?魣vila Dｄｅ L，Araújo GR，Silva M，et al.Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats[J].Arch Med Res，2013，44（3）：194-202.
相似文献/References:
[1]包薇萍,陈国芳,刘超.DPP-4抑制剂的肾保护作用[J].国际内分泌代谢杂志,2014,(05):337.[doi:10.3760/cma.j.issn.1673-4157.2014.05.014]
Bao Weiping,Chen Guofang,Liu Chao..Renal protective effects of dipeptidyl peptidase-4 inhibitors[J].International Journal of Endocrinology and Metabolism,2014,(03):337.[doi:10.3760/cma.j.issn.1673-4157.2014.05.014]